

Publikationen 2017

[Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase.](#)

Jawhar M, Naumann N, Schwaab J, Baurmann H, Casper J, Dang TA, Dietze L, Döhner K, **Hänel A**, Lathan B, Link H, Lotfi S, Maywald O, Mielke S, Müller L, Platzbecker U, Prümmer O, Thomssen H, Töpelt K, Panse J, Vieler T, Hofmann WK, Haferlach T, Haferlach C, Fabarius A, Hochhaus A, Cross NCP, Reiter A, Metzgeroth G.
Ann Hematol 2017, 96(9):1463-1470.

[Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE Trial.](#)

Middeke JM, **Herbst R**, Parmentier S, Bug G, **Hänel M**, Stuhler G, Schäfer-Eckart K, Rösler W, Klein S, Bethge W, Bitz U, Büttner B, Knoth H, Alakel N, Schaich M, **Morgner A**, Kramer M, Sockel K, von Bonin M, Stölzel F, Platzbecker U, Röllig C, Thiede C, Ehninger G, Bornhäuser M, Schetelig J.
Biol Blood Marrow Transplant 2017, 23(9):1491-1497.

[Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation \(ASCT\) in relapsed follicular lymphoma \(FL\): a retrospective study of the EBMT Lymphoma Working Party.](#)

Bento L, Boumendil A, Finel H, Le Gouill S, Amorim S, Monjanel H, Bouabdallah R, Bay JO, Nicolas-Virelizier E, McQuaker G, Rossi G, Johnson R, Huynh A, Ceballos P, Rambaldi A, Bachy E, Malladi R, Orchard K, Pohlreich D, Tilly H, Bonifazi F, Poiré X, Guilhot F, **Haenel A**, Crawley C, Metzner B, Gribben J, Russell NH, Damaj G, Thomson K, Dreger P, Montoto S.
Bone Marrow Transplant 2017, 52(8):1120-1125

[Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial.](#)

Huhn S, Weinhold N, Nickel J, Pritsch M, Hielscher T, Hummel M, Bertsch U, Huegle-Doerr B, Vogel M, Angermund R, **Hänel M**, Salwender HJ, Weisel K, Dürig J, Görner M, Kirchner H, Peter N, Graeven U, Lordick F, Hoffmann M, Reimer P, Blau IW, Jauch A, Dembowski K, Möhler T, Wuchter P, Goldschmidt H.
Bone Marrow Transplant 2017, 52(8):1194-1198.

[Evolution of NPM1-negative therapy-related myelodysplastic syndromes following curative treatment of NPM1-mutant AML.](#)

Herold S, Sockel K, Sayehli C, **Herbst R**, Dührsen U, Oelschlägel U, Böttner A, Hindahl H, Kullmer J, Helas S, Sauer M, Mohr B, Mies A, Bornhäuser M, Ehninger G, Röllig C, Thiede C, Platzbecker U.
Leukemia 2017 (in press)

[Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.](#)

Hehlmann R, Lauseker M, Saußeke S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Müller MC, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler MC, **Hänel M**, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne CA, Lindemann HW, Waller CF, Pfreundschuh M, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J.
Leukemia. 2017 (in press)

[High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients \(PRIMAIn study\).](#)

Fritsch K, Kasenda B, Schorb E, Hau P, Bloehdorn J, Möhle R, Löw S, Binder M, Atta J, Keller U, Wolf HH, Krause SW, Heß G, Naumann R, Sasse S, Hirt C, Lamprecht M, Martens U, **Morgner A**, Panse J, Frickhofen N, Röth A, Hader C, Deckert M, Fricker H, Ihorst G, Finke J, Illerhaus G.
Leukemia 2017, 31(4):846-852.

[Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.](#)

Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, **Hänel M**, Röllig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F.

J Clin Oncol 2017, 35(6):605-612.

Publikationen 2016

[Mammalian-target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes \(MDS\) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group \(D-MDS\).](#)

Wermke M, Schuster C, Nolte F, Al-Ali HK, Kiewe P, Schönefeldt C, Jakob C, von Bonin M, Hentschel L, Klut IM, Ehninger G, Bornhäuser M, Baretton G, Germing U, **Herbst R**, Haase D, Hofmann WK, Platzbecker U.

Br J Haematol 2016, 175(5):917-924

[Long-term follow-up of patients with relapsed or refractory non-Hodgkin's lymphoma receiving allogeneic stem cell transplantation.](#)

Link CS, **Mies F**, Scheele J, Kramer M, Schetelig J, Ordemann R, **Hänel M**, Bornhäuser M, Ehninger G, Kroschinsky F.

Bone Marrow Transplant 2016, 51(11):1527-1529

[Increase of T and B cells and altered BACH2 expression patterns in bone marrow trephines of imatinib-treated patients with chronic myelogenous leukaemia.](#)

Von Laffert M, **Hänel M**, Dietel M, Anagnostopoulos I, Jöhrens K.

Oncol Lett 2016, 12(4):2421-2428.

[Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms \(MPN\): a comparison between university hospitals, community hospitals, and office-based physicians.](#)

Kaifie A, Isfort S, Gattermann N, Hollburg W, Klausmann M, Wolf D, Maintz C, **Hänel M**, Goekkurt E, Göthert JR, Platzbecker U, Geer T, Parmentier S, Jost E, Serve H, Ehninger G, Berdel WE, Brümmendorf TH, Koschmieder S; Study Alliance Leukemia (SAL).

Ann Hematol 2016, 95(9):1399-1410.

[Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial.](#)

Schmitt M, Hückelhoven AG, Hundemer M, Schmitt A, Lipp S, Emde M, Salwender H, **Hänel M**, Weisel K, Bertsch U, Dürig J, Ho AD, Blau IW, Goldschmidt H, Seckinger A, Hose D.

Oncotarget. 2016 Aug 11.

[Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma \(MCL Younger\): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.](#)

Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, Szymczyk M, Bouabdallah R, Kneba M, Hallek M, Salles G, Feugier P, Ribrag V, Birkmann J, Forstpointner R, Haioun C, **Hänel M**, Casasnovas RO, Finke J, Peter N, Bouabdallah K, Sebban C, Fischer T, Dührsen U, Metzner B, Maschmeyer G, Kanz L, Schmidt C, Delarue R, Brousse N, Klapper W, Macintyre E, Delfau-Larue MH, Pott C, Hiddemann W, Unterhalt M, Dreyling M; European Mantle Cell Lymphoma Network.

Lancet 2016, 388(10044):565-75.

[Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial.](#)

Mai EK, Benner A, Bertsch U, Brossart P, **Hänel A**, Kunzmann V, Naumann R, Neben K, Egerer G, Ho AD, Hillengass J, Raab MS, Neubauer A, Peyn A, Ko YD, Peter N, Scheid C, Goldschmidt H. Br J Haematol 2016, 173(5):731-741

[Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.](#)

Herrlinger U, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfisch MW, Uhl M, Maciaczyk J, Grau S, Schnell O, **Hänel M**, Krex D, Vajkoczy P, Gerlach R, Kortmann RD, Mehdorn M, Tüttenberg J, Mayer-Steinacker R, Fietkau R, Brehmer S, Mack F, Stuplich M, Kebir S, Kohnen R, Dunkl E, Leutgeb B, Proescholdt M, Pietsch T, Urbach H, Belka C, Stummer W, Glas M. J Clin Oncol 2016, 34(14):1611-1619.

[Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms \(MPN\): analysis from the German SAL-MPN-registry.](#)

Kaifie A, Kirschner M, Wolf D, Maintz C, **Hänel M**, Gattermann N, Gökkurt E, Platzbecker U, Hollburg W, Göthert JR, Parmentier S, Lang F, Hansen R, Isfort S, Schmitt K, Jost E, Serve H, Ehninger G, Berdel WE, Brümmendorf TH, Koschmieder S; Study Alliance Leukemia (SAL). J Hematol Oncol 2016, 9:18.

[TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation.](#)

Middeke JM, Herold S, Rücker-Braun E, Berdel WE, Stelljes M, Kaufmann M, Schäfer-Eckart K, Baldus CD, Stuhlmann R, Ho AD, Einsele H, Rösler W, Serve H, **Hänel M**, Sohlbach K, Klesse C, Mohr B, Heidenreich F, Stölzel F, Röllig C, Platzbecker U, Ehninger G, Bornhäuser M, Thiede C, Schetelig J; Study Alliance Leukaemia (SAL). Br J Haematol 2016, 172(6):914-922.

[Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.](#)

Ho AD, Schetelig J, Bochtler T, Schaich M, Schäfer-Eckart K, **Hänel M**, Rösler W, Einsele H, Kaufmann M, Serve H, Berdel WE, Stelljes M, Mayer J, Reichle A, Baldus CD, Schmitz N, Kramer M, Röllig C, Bornhäuser M, Thiede C, Ehninger G; Study Alliance Leukemia. Biol Blood Marrow Transplant 2016, 22(3):462-469.

[Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia.](#)

Müller-Tidow C, Tschanter P, Röllig C, Thiede C, Koschmieder A, Stelljes M, Koschmieder S, Dugas M, Gerss J, Butterfaß-Bahloul T, Wagner R, Eveslage M, Thiem U, Krause SW, Kaiser U, Kunzmann V, Steffen B, Noppeney R, Herr W, Baldus CD, Schmitz N, Götze K, Reichle A, Kaufmann M, Neubauer A, Schäfer-Eckart K, **Hänel M**, Peceny R, Frickhofen N, Kiehl M, Giagounidis A, Görner M, Repp R, Link H, Kiani A, Naumann R, Brümmendorf TH, Serve H, Ehninger G, Berdel WE, Krug U; Study Alliance Leukemia Group. Leukemia 2016, 30(3):555-561.

[Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial.](#)

Middeke JM, **Herbst R**, Parmentier S, Bug G, **Hänel M**, Stuhler G, Schäfer-Eckart K, Rösler W, Klein S, Bethge W, Bitz U, Büttner B, Knoth H, Alakel N, Schaich M, **Morgner A**, Kramer M, Sockel K, von Bonin M, Stölzel F, Platzbecker U, Röllig C, Thiede C, Ehninger G, Bornhäuser M, Schetelig J. Leukemia 2016, 30(2):261-217.

[Karyotype complexity and prognosis in acute myeloid leukemia.](#)

Stölzel F, Mohr B, Kramer M, Oelschlägel U, Bochtler T, Berdel WE, Kaufmann M, Baldus CD, Schäfer-Eckart K, Stuhlmann R, Einsele H, Krause SW, Serve H, **Hänel M**, **Herbst R**, Neubauer A, Sohlbach K, Mayer J, Middeke JM, Platzbecker U, Schaich M, Krämer A, Röllig C, Schetelig J, Bornhäuser M, Ehninger G. Blood Cancer J. 2016, 6:e386.

[Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group \(OSHO\).](#)

Kahl C, Krahl R, Becker C, Al-Ali HK, Sayer HG, Schulze A, Herold M, **Hänel M**, Scholl S, Hochhaus A, Uharek L, Maschmeyer G, Haehling D, Junghanß C, Peter N, Kämpfe D, Kettner E, Heinicke T, Fischer T, Kreibich U, Wolf HH, Niederwieser D.
J Cancer Res Clin Oncol 2016, 142(1):305-315.

Publikationen 2015

[Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia \(SORAML\): a multicentre, phase 2, randomised controlled trial.](#)

Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, Baldus CD, Brandts CH, Kunzmann V, Einsele H, Krämer A, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, **Herbst R**, **Hänel M**, Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghanß C, Repp R, Heits F, Dürk H, Hase J, Klut IM, Illmer T, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Schetelig J, Kramer M, Berdel WE, Ehninger G; Study Alliance Leukaemia.
Lancet Oncol 2015, 16(16):1691-1699.

[Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML.](#)

Fabarius A, Kalmanti L, Dietz CT, Lauseker M, Rinaldetti S, Haferlach C, Göhring G, Schlegelberger B, Jotterand M, Hanfstein B, Seifarth W, **Hänel M**, Köhne CH, Lindemann HW, Berdel WE, Staib P, Müller MC, Proetel U, Balleisen L, Goebeler ME, Dengler J, Falge C, Kanz L, Burchert A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Brümmendorf TH, Edinger M, Hofmann WK, Pfirrmann M, Hasford J, Krause S, Hochhaus A, Saußebe S, Hehlmann R; SAKK and the German CML Study Group.
Ann Hematol 2015, 94(12):2015-2024.

[Bendamustine in heavily pre-treated patients with relapsed or refractory multiple myeloma.](#)

Stöhr E, Schmeel FC, Schmeel LC, **Hänel M**, Schmidt-Wolf IG; German Refractory Myeloma Study Group.
J Cancer Res Clin Oncol 2015, 141(12):2205-2212.

[Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology \(OSHO\) and the Study Alliance Leukemia \(SAL\).](#)

Thiel A, Schetelig J, Pönisch W, Schäfer-Eckart K, Aulitzky W, Peter N, Schulze A, Maschmeyer G, Neugebauer S, **Herbst R**, **Hänel A**, **Morgner A**, Kroschinsky F, Bornhäuser M, Lange T, Wilhelm M, Niederwieser D, Ehninger G, Fiedler F, **Hänel M**; East German Study Group Hematology/Oncology (OSHO); Study Alliance Leukemia (SAL).
Ann Oncol 2015, 26(7):1434-1440.

[Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia \(SAL\) AML 2003 trial.](#)

Schetelig J, Schaich M, Schäfer-Eckart K, **Hänel M**, Aulitzky WE, Einsele H, Schmitz N, Rösler W, Stelljes M, Baldus CD, Ho AD, Neubauer A, Serve H, Mayer J, Berdel WE, Mohr B, Oelschlägel U, Parmentier S, Röllig C, Kramer M, Platzbecker U, Illmer T, Thiede C, Bornhäuser M, Ehninger G; Study Alliance Leukemia.
Leukemia 2015, 29(5):1060-1068

[Two cycles of risk-adapted consolidation therapy in patients with acute promyelocytic leukemia. Results from the SAL-AIDA2000 trial.](#)

Röllig C, Schäfer-Eckardt K, **Hänel M**, Kramer M, Schaich M, Thiede C, Oelschlägel U, Mohr B, Wagner T, Einsele H, Krause SW, Bodenstein H, Martin S, Stuhlmann R, Ho AD, Bornhäuser M, Ehninger G, Schuler U, Platzbecker U.
Ann Hematol 2015, 94(4):557-563

[Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial.](#)

Röllig C, Bornhäuser M, Kramer M, Thiede C, Ho AD, Krämer A, Schäfer-Eckart K, Wandt H, **Hänel M**, Einsele H, Aulitzky WE, Schmitz N, Berdel WE, Stelljes M, Müller-Tidow C, Krug U, Platzbecker U, Wermke M, Baldus CD, Krause SW, Stölzel F, von Bonin M, Schaich M, Serve H, Schetelig J, Ehninger G.
J Clin Oncol 2015, 33(5):403-410.

Publikationen 2014

[Optimization of rituximab for the treatment of diffuse large B-cell lymphoma \(II\): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group.](#)

Pfreundschuh M, Poeschel V, Zeynalova S, **Hänel M**, Held G, Schmitz N, Viardot A, Dreyling MH, Hallek M, Mueller C, Wiesen MH, Witzens-Harig M, Truemper L, Keller U, Rixecker T, Zwick C, Murawski N.
J Clin Oncol 2014, 32(36):4127-4133.

[Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia \(CML\) patients in chronic phase on treatment with imatinib.](#)

Hanfstein B, Shlyakhto V, Lauseker M, Hehlmann R, Saussele S, Dietz C, Erben P, Fabarius A, Proetel U, Schnittger S, Krause SW, Schubert J, Einsele H, **Hänel M**, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pffirmann M, Hasford J, Hofmann WK, Hochhaus A, Müller MC; SAKK and the German CML Study Group.
Leukemia 2014, 28(10):1988-1992.

[Optimization of rituximab for the treatment of DLBCL \(I\): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL.](#)

Murawski N, Pfreundschuh M, Zeynalova S, Poeschel V, **Hänel M**, Held G, Schmitz N, Viardot A, Schmidt C, Hallek M, Witzens-Harig M, Trümper L, Rixecker T, Zwick C.
Ann Oncol 2014, 25(9):1800-1806.

[Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.](#)

Hanfstein B, Lauseker M, Hehlmann R, Saussele S, Erben P, Dietz C, Fabarius A, Proetel U, Schnittger S, Haferlach C, Krause SW, Schubert J, Einsele H, **Hänel M**, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pffirmann M, Hasford J, Hofmann WK, Hochhaus A, Müller MC; SAKK and the German CML Study Group.
Haematologica 2014, 99(9):1441-1447.

[The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas.](#)

Murawski N, Held G, Ziepert M, Kempf B, Viardot A, **Hänel M**, Witzens-Harig M, Mahlberg R, Rube C, Fleckenstein J, Zwick C, Glass B, Schmitz N, Zeynalova S, Pfreundschuh M.
Blood 2014, 124(5):720-728

[Older patients with chronic myeloid leukemia \(≥65 years\) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV.](#)

Proetel U, Pletsch N, Lauseker M, Müller MC, Hanfstein B, Krause SW, Kalmanti L, Schreiber A, Heim D, Baerlocher GM, Hofmann WK, Lange E, Einsele H, Wernli M, Kremers S, Schlag R, Müller L, **Hänel M**, Link H, Hertenstein B, Pffirmann M, Hochhaus A, Hasford J, Hehlmann R, Sauße S; German Chronic Myeloid Leukemia Study Group; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK).
Ann Hematol 2014, 93(7):1167-1176.

[Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma.](#)

Held G, Murawski N, Ziepert M, Fleckenstein J, Pöschel V, Zwick C, Bittenbring J, **Hänel M**, Wilhelm S, Schubert J, Schmitz N, Löffler M, Rube C, Pfreundschuh M.
J Clin Oncol 2014, 32(11):1112-1118.

[Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.](#)

Scheid C, Sonneveld P, Schmidt-Wolf IG, van der Holt B, el Jarari L, Bertsch U, Salwender H, Zweegman S, Blau IW, Vellenga E, Weisel K, Pfreundschuh M, Jie KS, Neben K, van de Velde H, Duehrsen U, Schaafsma MR, Lindemann W, Kersten MJ, Peter N, **Hänel M**, Croockewit S, Martin H, Wittebol S, Bos GM, van Marwijk-Kooy M, Wijermans P, Goldschmidt H, Lokhorst HM.
Haematologica 2014, 99(1):148-154.

Publikationen 2013

[Early intervention with allogeneic hematopoietic cell transplantation during chemotherapy-induced aplasia in patients with high-risk acute myeloid leukemia.](#)

Stölzel F, Platzbecker U, Mohr B, Röllig C, Middeke JM, Thiede C, Füssel M, **Hänel M**, Schaich M, Ehninger G, Schetelig J, Bornhäuser M.
Leukemia 2013, 27(10):2068-2072.

[Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.](#)

Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lübbert M, **Hänel M**, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Döhner K, Sauer M, Ganser A, Amadori S, Mandelli F, Döhner H, Ehninger G, Schlenk RF, Platzbecker U; Gruppo Italiano Malattie Ematologiche dell'Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia.
N Engl J Med 2013, 369(2):111-121.

[High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial.](#)

Schaich M, Parmentier S, Kramer M, Illmer T, Stölzel F, Röllig C, Thiede C, **Hänel M**, Schäfer-Eckart K, Aulitzky W, Einsele H, Ho AD, Serve H, Berdel WE, Mayer J, Schmitz N, Krause SW, Neubauer A, Baldus CD, Schetelig J, Bornhäuser M, Ehninger G.
J Clin Oncol 2013, 31(17):2094-2102.

[Acute leukemias of ambiguous lineage in adults: molecular and clinical characterization.](#)

Heesch S, Neumann M, Schwartz S, Bartram I, Schlee C, Burmeister T, **Hänel M**, Ganser A, Heuser M, Wendtner CM, Berdel WE, Gökbüget N, Hoelzer D, Hofmann WK, Thiel E, Baldus CD.
Ann Hematol 2013, 92(6):747-758.

[Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation.](#)

Schorb E, Kasenda B, Atta J, Kaun S, **Morgner A**, Hess G, Elter T, von Bubnoff N, Dreyling M, Ringhoffer M, Krause SW, Derigs G, Klimm B, Niemann D, Fritsch K, Finke J, Illerhaus G.
Haematologica 2013, 98(5):765-770.

[Impact of allogeneic haematopoietic stem cell transplantation in patients with abn1\(17p\) acute myeloid leukaemia.](#)

Mohr B, Schetelig J, Schäfer-Eckart K, Schmitz N, **Hänel M**, Rösler W, Frickhofen N, Link H, Neubauer A, Schuler U, Platzbecker U, Middeke JM, Ehninger G, Bornhäuser M, Schaich M, Stölzel F; Study Alliance Leukaemia (SAL).
Br J Haematol 2013, 161(2):237-244.

[Phase II study of central nervous system \(CNS\)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas.](#)
Korfel A, Elter T, Thiel E, **Hänel M**, Möhle R, Schroers R, Reiser M, Dreyling M, Eucker J, Scholz C, Metzner B, Röth A, Birkmann J, Schlegel U, Martus P, Illerhaus G, Fischer L.
Haematologica 2013, 98(3):364-370.

[Unusual clinico-pathological features in primary Hodgkin's lymphomas of the central nervous system.](#)
Gessi M, Kuchelmeister K, Kellner U, Ritter M, **Morgner A**, Urbach H, **Hänel M**, Simon M, Pietsch T.
Acta Neurochir (Wien) 2013, 155(1):19-24.

Publikationen 2012

[Conventional chemotherapy \(CHOEP-14\) with rituximab or high-dose chemotherapy \(MegaCHOEP\) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial \(DSHNHL 2002-1\).](#)

Schmitz N, Nickelsen M, Ziepert M, **Haenel M**, Borchmann P, Schmidt C, Viardot A, Bentz M, Peter N, Ehninger G, Doelken G, Ruebe C, Truemper L, Rosenwald A, Pfreundschuh M, Loeffler M, Glass B; German High-Grade Lymphoma Study Group (DSHNHL).
Lancet Oncol 2012, 13(12):1250-1259.

[Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study.](#)

Wandt H, Schaefer-Eckart K, Wendelin K, Pilz B, Wilhelm M, Thalheimer M, Mahlke U, Ho A, Schaich M, Kramer M, Kaufmann M, Leimer L, Schwerdtfeger R, Conradi R, Dölken G, Klenner A, **Hänel M**, **Herbst R**, Junghans C, Ehninger G; Study Alliance Leukemia.
Lancet 2012, 380(9850):1309-1316.

[Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia \(CML\).](#)

Hanfstein B, Müller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, Schnittger S, Haferlach C, Göhring G, Proetel U, Kolb HJ, Krause SW, Hofmann WK, Schubert J, Einsele H, Dengler J, **Hänel M**, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Branford S, Hughes TP, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Sauße S, Hochhaus A; SAKK; German CML Study Group.
Leukemia 2012, 26(9):2096-2102.

[Long-term follow-up of high-dose chemotherapy with autologous stem-cell transplantation and response-adapted whole-brain radiotherapy for newly diagnosed primary CNS lymphoma: results of the multicenter Ostdeutsche Studiengruppe Hamatologie und Onkologie OSHO-53 phase II study.](#)

Kiefer T, Hirt C, Späth C, Schüler F, Al-Ali HK, Wolf HH, **Herbst R**, Maschmeyer G, Helke K, Kessler C, Niederwieser D, Busemann C, Schroeder H, Vogelgesang S, Kirsch M, Montemurro M, Krüger WH, Dölken G; Ostdeutsche Studiengruppe Hämatologie und Onkologie.
Ann Oncol 2012, 23(7):1809-1812.

[Treatment with Thalidomide and Cyclophosphamide \(TCID\) is Superior to Vincristine \(VID\) and to Vinorelbine \(VRID\) Regimens in Patients with Refractory or Recurrent Multiple Myeloma.](#)

Auel B, Goldschmidt H, Geer T, Moehler TM, Platzbecker U, Naumann R, Blau I, **Hänel M**, Knauf W, Nüchel H, Salwender HJ, Scheid C, Weisel K, Gorschlüter M, Glasmacher A, Schmidt-Wolf IG; German Refractory Myeloma Study Group.
Indian J Hematol Blood Transfus 2012, 28(2):67-76.

Publikationen 2011

[Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study.](#)

Schimmer AD, Herr W, **Hänel M**, Borthakur G, Frankel A, Horst HA, Martin S, Kassis J, Desjardins P, Seiter K, Fiedler W, Noppeney R, Giagounidis A, Jacob C, Jolivet J, Tallman MS, Koschmieder S.
Clin Lymphoma Myeloma Leuk 2011, 11(5):433-438

[Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon- \$\alpha\$ in newly diagnosed chronic myeloid leukemia.](#)

Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Müller MC, Pletsch N, Proetel U, Haferlach C, Schlegelberger B, Balleisen L, **Hänel M**, Pfirrmann M, Krause SW, Nerl C, Pralle H, Gratwohl A, Hossfeld DK, Hasford J, Hochhaus A, Saussele S.
J Clin Oncol 2011, 29(12):1634-1642